Difference between revisions of "Serplulimab (Hansizhuang)"
Jump to navigation
Jump to search
m |
m |
||
| Line 10: | Line 10: | ||
==Diseases for which it is used== | ==Diseases for which it is used== | ||
| + | *[[MSI-H or dMMR|MSI-H or dMMR solid tumors (tissue-agnostic)]] | ||
*[[Small cell lung cancer]] | *[[Small cell lung cancer]] | ||
| + | |||
| + | ==History of changes in NMPA indication== | ||
| + | *3/25/2022: Approved for the treatment of adult patients with advanced unresectable or metastatic MSI-H (Microsatellite Instability-High) solid tumors that have failed to respond to previous standard treatments. | ||
==Also known as== | ==Also known as== | ||
| Line 21: | Line 25: | ||
[[Category:Anti-PD-1 antibodies]] | [[Category:Anti-PD-1 antibodies]] | ||
| + | [[Category:MSI-H or dMMR medications]] | ||
[[Category:Small cell lung cancer medications]] | [[Category:Small cell lung cancer medications]] | ||
[[Category:NMPA approved drugs]] | [[Category:NMPA approved drugs]] | ||
Revision as of 11:20, 30 September 2022
General information
Class/mechanism: PD-1 receptor antibody.
Route: IV
Extravasation: no information
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.
Toxicity management
Diseases for which it is used
History of changes in NMPA indication
- 3/25/2022: Approved for the treatment of adult patients with advanced unresectable or metastatic MSI-H (Microsatellite Instability-High) solid tumors that have failed to respond to previous standard treatments.
Also known as
- Code name: HLX10
- Brand name: Hansizhuang